The DOI matches its Crossref record.
In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346)
Open accessAbstract
The antifungal activity of BMS-207147 (also known as ER-30346) was compared to those of itraconazole and fluconazole against 250 strains of fungi representing 44 fungal species. MICs were determined by using the National Committee for Clinical Laboratory Standards (NCCLS)-recommended broth macrodilution method for yeasts, which was modified for filamentous fungi. BMS-207147 was about two- to fourfold more potent than itraconazole and about 40-fold more active than fluconazole against yeasts. With the NCCLS-recommended resistant MIC breakpoints of ≥1 μg/ml for itraconazole and of ≥64 μg/ml for fluconazole against Candida spp., itraconazole and fluconazole were inactive against strains of Candida krusei and Candida tropicalis . In contrast, all but 9 (all C. tropicalis ) of the 116 Candida strains tested had BMS-207147 MICs of <1 μg/ml. The three triazoles were active against about half of the Candida glabrata strains and against all of the Cryptococcus neoformans strains tested. The three triazoles were fungistatic to most yeast species, except for BMS-207147 and itraconazole, which were fungicidal to cryptococci. BMS-207147 and itraconazole were inhibitory to most aspergilli, and against half of the isolates, the activity was cidal. BMS-207147 and itraconazole were active, though not cidal, against most hyaline Hyphomycetes (with the exception of Fusarium spp. and Pseudallescheria boydii ), dermatophytes, and the dematiaceous fungi and inactive against Sporothrix schenckii and zygomycetes. Fluconazole, on the other hand, was inactive against most filamentous fungi with the exception of dermatophytes other than Microsporum gypseum . Thus, the spectrum and potency of BMS-207147 indicate that it should be a candidate for clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Infections due to emerging and uncommon medically important fungal pathogens
Walsh, T. J., Groll, A., Hiemenz, J., Fleming, R., Roilides, E., & Anaissie, E. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00839.x · Cited by 601
Melanized Fungi in Human Disease
Revankar, S. G., & Sutton, D. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-10 · Cited by 569
In vitro susceptibilities of zygomycetes to conventional and new antifungals
Dannaoui, E. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg020 · Cited by 314
Antifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310
Uncommon opportunistic fungi: new nosocomial threats
Groll, A. H., & Walsh, T. J. (2001) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2001.tb00005.x · Cited by 305
Espinel-Ingroff, A. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.954-958.2001 · Cited by 296
Pfaller, M. A., Jones, R. N., Doern, G. V., Fluit, A. C., Verhoef, J., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., & Hollis, R. J. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00046-2 · Cited by 264
Zygomycosis (mucormycosis): emerging clinical importance and new treatments
Greenberg, R. N., Scott, L. J., Vaughn, H. H., & Ribes, J. A. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200412000-00003 · Cited by 258
Espinel-Ingroff, A., Fothergill, A., Peter, J., Rinaldi, M. G., & Walsh, T. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.9.3204-3208.2002 · Cited by 203
“and other moulds have been evaluated and compared to those of amphotericin B and itraconazole (3, 7, 11, 13, 14, 16, 17, 21, 24, 25).”
MethodResultInfluentialNew and emerging treatments for fungal infections
Pasqualotto, A. C., & Denning, D. W. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm428 · Cited by 173
Espinel-Ingroff, A., Chaturvedi, V., Fothergill, A., & Rinaldi, M. G. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.10.3776-3781.2002 · Cited by 167
Espinel-Ingroff, A., Bartlett, M., Chaturvedi, V., Ghannoum, M., Hazen, K. C., Pfaller, M. A., Rinaldi, M., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1828-1835.2001 · Cited by 83
Metadata
- Authors
- Fung-Tomc, J. C., Huczko, E., Minassian, B., & Bonner, D. P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1998-02
- Volume
- 42
- Issue
- 2
- Pages
- 313-318
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2164811538
- Cited by
- 182
- References
- 0
- FWCI
- 9.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.